{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"13"}],"units":"Participants"}],"description":"Adverse Events, Serious Adverse Events, physical examination and biological changes.","groups":[{"description":"every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.","id":"OG000","title":"Arm A: IPH2101 0.2mg/Kg"},{"description":"every 4 weeks by intravenous route over 1 hour, for 4 or up to 8 cycles.","id":"OG001","title":"Arm B: IPH2101 2mg/kg"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"from screening visit to the End of Study (at each study visit)","title":"Safety Assessment","type":"SECONDARY","unitOfMeasure":"participants"}